# Allen Jacques

Allen Jacques writes about pharma and biopharma supply chains, including inventory, planning, manufacturing capacity, and the connection between operational decisions and long-term strategy.

- Profile: https://b2binfluencer.marketing/creators/allen-jacques/
- LinkedIn: https://www.linkedin.com/in/allenjacques
- LinkedIn followers: 3,551
- Topics: supply-chain
- Based on 13 dated posts, latest 2026-09-16

## Summary

Most useful for pharma and biopharma supply chain thought leadership on inventory and capacity planning.

- Best for: A biopharma supply chain software webinar on multi-echelon inventory optimization.
- Not for: A consumer or general SMB inventory app campaign focused on reach and sign-ups.
- Check first: Confirm commercial terms, recent post engagement, and audience demographics before contacting them.

### Takeaways

- Cutting inventory can shorten shelf life, delay defect discovery, and create obsolete packaging.
- AI will not fix a supply chain that is not connected end to end.
- Supply chain should help build long-range plans from the outset, not review late.

## Main ideas

- **Cutting inventory carries costs the cash-flow conversation misses**: In a post titled "Three reasons to reduce inventory, and cashflow isn't one of them," Allen Jacques argues that finance-led inventory reviews capture payables and receivables but miss what buffers and long lead times do to the product itself. Three costs get named: shelf life consumed before a product reaches the customer, quality defects discovered downstream after months of work-in-progress and bulk inventory sit waiting on testing, release, and review, and delayed new-product introductions when stock of old versions, including old regulatory artwork, makes a fast launch too expensive. The proposed countermeasure is multi-echelon inventory optimization, which Allen Jacques describes as a way to lean out inventory without hurting service levels.
- **AI will not rescue a supply chain that is not connected end to end**: Allen Jacques states the position plainly: AI will not save a supply chain that is not connected end to end; it will help a company fail faster. The reasoning treats structural connectivity as a precondition for analytics, not something analytics can substitute for. The post points to a longer piece on the subject. This is a recurring stance: the inventory post's argument about buffer costs hidden across echelons points in the same direction. The losses come from structural disconnection, not weak prediction.
- **Supply chain belongs in the ten-year plan as a builder, not a late reviewer**: Writing about biopharma capacity, Allen Jacques argues that people who understand manufacturing reality are often absent when long-range plans are made. The fix, they say, is not a better forecasting model but giving supply chain a real seat at the strategic planning table from day one, bridging what is commercially assumed and what is operationally possible. The argument rests on the shape of biopharma: long construction and validation timelines, multi-jurisdiction regulatory approval, clinical pipelines where fewer than 10% of molecules reach market, and demand that is nearly impossible to forecast until Phase III results arrive. Capacity also shifts through growth, stabilization, and decline after loss of exclusivity, and through process-development yield and OEE gains that create capacity nobody planned for. A plan that ignores those dynamics, they write, is not built on much, and the gap compounds quietly over years.
- **Priorities in Allen Jacques’s posts: senior industry convening and planning-platform news**: Two posts show where attention goes rather than make an argument. One announces team sponsorship of LogiPharma Digital Connect 2026, describing curated one-to-one meetings and peer discussions with 100 senior European life sciences supply chain and digital leaders. Topics include AI, automation, planning, and digital transformation. The other is a short congratulations post noting that nine OMP customers appear in the Gartner Supply Chain Top 25 and naming two individuals at AstraZeneca and J&J. Together, they suggest a preference for executive, curated life-sciences settings over broad-reach content, and an interest in planning-platform adoption and analyst recognition. The posts indicate priorities and audience, not ideas Jacques has developed.

## Work to read

- [Three reasons to reduce inventory—and cash flow isn’t one of them](https://www.linkedin.com/posts/allenjacques_three-reasons-to-reduce-inventory-and-cashflow-activity-7482451355496783872-k4S2)
- [I’ve spent my career inside pharma and biopharma supply chains](https://www.linkedin.com/posts/allenjacques_ive-spent-my-career-inside-pharma-and-biopharma-activity-7467218283440820224-S38l)
- [We’re proud to be sponsoring LogiPharma Digital Connect 2026](https://www.linkedin.com/posts/allenjacques_were-proud-to-be-sponsoring-logipharma-digital-activity-7506017252593422336-3pxV)

## Brand relationships

- **Pfizer** (employment)
- **LogiPharma** (sponsor)
- **OMP** (mention)

## Partnerships

No sponsorship or partnership offer is documented in the material reviewed for Allen Jacques. The only partnership-adjacent item is a post announcing that the poster's organisation is sponsoring LogiPharma Digital Connect 2026, which the post describes as bringing together senior life-sciences supply chain and digital leaders through curated one-to-one meetings and peer discussions, with a link to request an invitation to the event. That sponsorship is paid for by Allen Jacques's side, not a published format a brand can buy from them, and the link is an event invitation request rather than a partnership inquiry route. A biopharma supply chain software company planning a thought-leadership webinar on multi-echelon inventory optimization should treat commercial terms as unconfirmed and ask directly, rather than assume a standard webinar, sponsored-post, or speaking package exists.

## Alternatives

- Imran Choudhery, M.S., CSCP: Pick Imran Choudhery when a software buyer wants a session for utility or asset-heavy operations rather than pharma, or needs to understand the distinction between demand and supply planning and how min-max reorder levels are set and maintained. Two posts make the case directly. The first (15 July 2026) separates what demand planning owns from what supply planning owns, then lists the consequences of blurring them into one role: shortages and stockouts, expediting and firefighting, lower forecast accuracy, excess and obsolete inventory, weaker service levels, higher operating costs and more cash tied up. The second (1 September 2026) explains min-max planning as a balance between stockouts and tied-up capital, and identifies the inputs that should drive the levels: average usage, storm and emergency demand variability, supplier lead times, safety stock needs, storage and yard constraints, and construction or customer service requirements. For a sponsor selling planning and inventory software to utilities, this is closer to buyers’ daily work than pharma shelf-life examples.
- Dan Lewis: Pick Dan Lewis when a sponsor wants a current-events segment on the life sciences industry, or a voice on digital manufacturing, automation and project delivery in pharma facilities—not inventory optimization mechanics. One post (18 May 2026) is a news digest covering Bristol Myers Squibb's licensing deal with Jiangsu Hengrui, FDA leadership departures, Takeda's 4,500 job cuts, Mounjaro overtaking Keytruda, Daiichi Sankyo's oncology revenue target, an INTERPOL seizure of six million illicit medicines, the EU's provisional Critical Medicines Act deal, Moderna's mRNA hantavirus research, Isomorphic Labs' $2.1B raise and other deal and funding items. The second (4 September 2026) announces Project Farma's completed acquisition of SimoTech and argues that engineering, quality, automation, digital systems and operations must be aligned across the facility lifecycle rather than optimized one discipline at a time.
- Jessie Schwartz: Pick Jessie Schwartz when the campaign moves upstream to packaging and sustainability, or when the buyer’s real obstacle is cross-functional data rather than inventory policy. One post (27 August 2026), promoting a LinkedIn Live session, captures the question packaging leaders keep asking after the first compliance wave: registered, reported, fees paid, now what? It argues that meeting the reporting deadline is not the same as building a system for escalating requirements and multi-state complexity. Teams making headway connect packaging data to finance, procurement, legal and engineering rather than adding tools or spreadsheet headcount. The second (24 August 2026) examines Oregon's Recycling Modernization Act, noting producer funding for more than 36,000 recycling carts, 11 collection trucks, 34 RecycleOn Centers and $30 million in sorting-facility upgrades. It then asks how packaging design trade-offs shift as collection and sorting change: lightweighting that risks compression strength, barrier performance or damage rates, and material changes that work only if the package can be collected, sorted and processed at scale.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/